CureDuchenne Blog

WMS 2021 Day 5: Late-breaking News

In WMS 2021’s final day and “late-breaking news” session, Capricor Therapeutics announced positive final data from its Phase 2 HOPE-2 clinical trial in Duchenne patients treated with CAP-1002. HOPE-2 was […]

WMS 2021 Day 4: Clinical Trial Updates

WMS 2021 on Thursday, September 23rd was a full day of oral and poster presentations, and we’ll highlight some Duchenne clinical trial updates covered. Solid Biosciences – SGT-001 micro-dystrophin gene […]

WMS 2021 Day 3: Opening Lecture and Debates

WMS 2021’s agenda on Wednesday, September 22nd was not so much about specific diseases, but rather major and timely research themes across all of biology.  The day started with a […]

WMS 2021 Day 1: Industry Symposia

Monday, September 20th was the first day of the WMS 2021 Virtual Congress, and a day devoted to symposia sponsored by various companies developing therapeutic treatments for neuromuscular disorders.  Most […]

Duchenne SSA Benefits Now Fast-tracked

Duchenne SSA Benefits Now Fast-tracked

CureDuchenne Cares Advocacy Efforts Succeed in Adding Duchenne to the Social Security Administration Compassionate Allowance List (CAL) Social Security Disability Insurance (SSDI) benefits are a financial lifeline for millions of […]

Announcing the NEW DuchenneXchange

Built by the community, for the community, the DuchenneXchange has offered a secure place to inform, inspire and empower those living with Duchenne since its inception in 2018. By offering […]